Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Pharmaceutical form:Suspension for injection in a pre-filled syringe Route of administration:IM injection”In the company’s words, NCT07941622 on ClinicalTrials.gov
- Tested for
- Haemophilus Influenzae Type b Immunisation, Hepatitis B Immunisation, Polio Immunization, Pertussis Immunisation, Diphtheria Immunisation, Tetanus Immunisation
- Main trialPhase 3
- “The purpose of this study is to measure the safety and immunogenicity of Hexaxim given at 2, 4, and 6 MoA compared with Pentaxim given at 2, 4, and 6 MoA plus a monovalent Hep B vaccine given at 1 and 6 MoA in healthy Chinese infants born to HBsAg seronegative mothers. Study details include: * The study duration per participant will be approximately 18 months. * The study vaccines administration: * Group 1: for the primary series vaccination, Hexaxim will be administered 3 doses at 2, 4, and 6 MoA. * Group 2: for the primary series vaccination, Pentaxim will be administered 3 doses at 2, 4,…”In the company’s words, NCT07941622 on ClinicalTrials.gov
Coming up1
- 27 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07941622
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 27 Apr 2028 | Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026